Multi-drug therapies for tuberculosis treatment
The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.
1. A pharmaceutical composition consisting essentially of a pharmaceutically effective amount of a combination of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) prothionamide or bedaquiline.
2. A pharmaceutical composition comprising a pharmaceutically effective amount of a combination of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) bedaquiline.
3. The pharmaceutical composition of claim 1 , wherein the combination consists essentially of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) prothionamide.
4. A method of treating tuberculosis in a subject in need thereof, comprising
administering to the patient a therapeutically effective amount of (i) a drug combination of consisting essentially of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) prothionamide or bedaquiline or (ii) a drug combination comprising a pharmaceutically effective amount of a combination of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) bedaquiline.
5. The method of claim 4 , wherein one or more of (a)-(d) in the combination is administered sequentially.
6. The method of claim 4 , wherein one or more of (a)-(d) is administered concurrently.
7. The method of claim 4 , wherein the subject is a mammal.
8. The method of claim 7 , wherein the mammal is a human.
9. The method of claim 4 , wherein the combination consists essentially of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) bedaquiline.
10. The method of claim 4 , wherein the combination consists essentially of (a) clofazimine, (b) ethambutol, (c) pyrazinamide, and (d) prothionamide.
11. The method of claim 4 , wherein the tuberculosis is caused by Mycobacterium tuberculosis.
12. The method of claim 4 , wherein the tuberculosis is Multi-drug resistant TB.
13. The method of claim 4 , wherein the tuberculosis is Extensively drug-resistant TB.
14. The method of claim 4 , wherein the tuberculosis is latent TB.
15. The pharmaceutical composition of claim 1 , wherein the combination is formulated into a single oral dosage form.
16. The pharmaceutical composition of claim 15 , wherein the single oral dosage form is a tablet, gelatin capsule, pill, troche, elixir, or suspension.
17. The method of claim 4 , wherein the combination is formulated into a single oral dosage form.